P04-36. HIV-1-speficic antibody dependant cellular cytotoxicity (ADCC) médiated by primary NK cells door Penichon J, Decoville T, Holl V, Delaporte M, Moog C

Algebraic methods for nonlinear control systems / door Conte, G., 1951-, Moog, C. H., 1955-, Perdon, A. M.

Volledige tekst

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection door Moog C, Schmidt S, Decoville T, Penichon J, Lederle A, Holl V

P04-27. Monoclonal neutralizing antibodies inhibit HIV-1 transfer from immature dendritic cells to human primary CD4 T-lymphocytes door Aubertin A, Schmidt S, Decoville T, Peressin M, Holl V, Xu K, Moog C

Non-neutralizing IgG anti-PID antibodies decreased viral load following high dose vaginal challenge of non-human primates door Moog C, Dereuddre-Bosquet N, Biedma M, Schmidt S, Decoville T, Mangeot I, Zolla-Pazner S, Vcelar B, Katinger D, Holl V, Le Grand R

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group door Polonis V, Osmanov S, Morris L, Moog C, Montefiori D, Malnati M, Lopalco L, Jansson M, Holmes H, Heyndrickx L, Heath A, Fenyö E, Bongertz V, Alcami J, Scarlatti G, Ramaswamy M, Sattentau Q, Schuitemaker H, Wrin T

Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group door Scarlatti, G, Alcami, J, Bongertz, V, Fenyo, E, Heath, A, Heyndrickx, L, Holmes, H, Jansson, M, Lopalco, L, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Ramaswamy, M, Sattentau, Q, Schuitemaker, H, Wrin, T

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans door Katinger D, Wagner A, Luque I, Crespillo S, Conejero-Lara F, Roger M, Martin C, Mouz N, Mourao S, Farsang A, Notka F, Malcolm K, Bosquet N, Le Grand R, Moog C, Cope A, Shattock R, Lewis DJ, El Habib R

Standardization of HIV Neutralization Assays for Use in Vaccine Research and Clinical Trials: Results from the NeutNet Working Group door Scarlatti, G, Alcami, J, Bongertz, V, Dispinseri, S, Donners, H, Fenyo, E, Heath, A, Heyndrickx, L, Holmes, H, Jassoy, C, Lusso, P, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Sattentau, Q, Schuitemaker, H, Sutthent, R, Wrin, T, Zolla-Pazner, S

International network for comparison of HIV neutralization assays: the NeutNet report II. door Heyndrickx, L, Heath, A, Sheik-Khalil, E, Alcami, J, Bongertz, V, Jansson, M, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Ramaswamy, M, Sattentau, Q, Tolazzi, M, Schuitemaker, H, Willems, B, Wrin, T, Fenyo, E, Scarlatti, G

International network for comparison of HIV neutralization assays: the NeutNet report. door Fenyo, E, Heath, A, Dispinseri, S, Holmes, H, Lusso, P, Zolla-Pazner, S, Donners, H, Heyndrickx, L, Alcami, J, Bongertz, V, Jassoy, C, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Sattentau, Q, Schuitemaker, H, Sutthent, R, Wrin, T, Scarlatti, G